Compare MBAI & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBAI | ADVB |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 8.6M |
| IPO Year | 2014 | 2023 |
| Metric | MBAI | ADVB |
|---|---|---|
| Price | $6.30 | $9.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 61.4K | ★ 244.9K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 5.21 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.79 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.95 | $0.19 |
| 52 Week High | $10.21 | $24.23 |
| Indicator | MBAI | ADVB |
|---|---|---|
| Relative Strength Index (RSI) | 58.95 | 50.99 |
| Support Level | $1.19 | $3.95 |
| Resistance Level | $10.21 | $9.50 |
| Average True Range (ATR) | 0.37 | 1.05 |
| MACD | -0.31 | -0.01 |
| Stochastic Oscillator | 11.04 | 50.83 |
MBody AI Ltd is an embodied artificial intelligence company. Its core technology is the MBody AI Orchestrator (Orchestrator), a proprietary, hardware-agnostic software platform that serves as an intelligence layer designed to enable autonomous systems to operate, coordinate, and improve more effectively. MBody AI does not manufacture robots; it makes third-party robots more intelligent and coordinated through the Orchestrator and deploys them at customer sites together with its software and related services. Each deployment is designed to generate proprietary operational data. Its initial commercial focus is the hospitality industry, with potential applications across other labor-intensive sectors, including warehousing, office management, and healthcare.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.